Chronic myeloid leukaemia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• ABL1 12
• TP53 1
• JAK 1
• AKT 0
• IDH 4
• ERK 0
• FLT3 2
• PI3K 0
• JNK 0
• STAT3 0
• BCL-2 2
• CD19 1
• HSP90 0
• KIT 1
• PDGFR 0
• CSF1R 2
• HDAC 0
• HIF-1 0
• IL-1 2
• MAPK 0
• PPAR 0
• AMPK 0
• CD123 0
• CD38 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• mTOR 0
• NLRP3 0
• NRF2 0
• RAS 0
• RUNX1 0
• BTK 0
• CD20 0
• CD22 0
• CD33 0
• CD40 0
• CD47 1
• CTLA-4 0
• CXCR4 0
• G6PD 0
• GLP-1 0
• IL-15 0
• IL-6 1
• KRAS 0
• MEK 1
• MYC 0
• NPM1 0
• NRAS 0
• PD-1 0
• PRMT5 0
• PTEN 0
• SGLT2 0
• SIRT1 0
• TIM-3 0
• YAP 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 30+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor

  NCT04216563· M.D. Anderson Cancer Center· Updated 2 Mar 2026

  “75% \< Participants, Administrativley Complete”Registry text, quoted unchanged. Source

• Terminated

  Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

  NCT03576547· M.D. Anderson Cancer Center· Updated 8 May 2025

  “The study was terminated early due to slow accrual and low level of interest both by the sponsor and by the department”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

  NCT01784068· Novartis Pharmaceuticals· Source

• Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation

  NCT06427811· Novartis Pharmaceuticals· Source

• Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

  NCT06514534· Novartis Pharmaceuticals· Source

• Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

  NCT02467270· Takeda· Source

• Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

  NCT04666259· Novartis Pharmaceuticals· Source

• Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

  NCT05384587· Novartis Pharmaceuticals· Source

• Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response

  NCT02852486· University of Campinas, Brazil· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 4
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 2
• Gene Expression Profiling 6
• Sequence Analysis, RNA 2
• Exome Sequencing 1
• Proteomics 5
• Metabolomics 3
• Mass Spectrometry 2
• Flow Cytometry 13
• Xenograft Model Antitumor Assays 19
• Magnetic Resonance Imaging 4
• Machine Learning 3
• Cohort Studies 9
• Genome-Wide Association Study 3

See which targets of this disease your abstract mentions, and go to the people working on them.